Published in J Antimicrob Chemother on February 07, 2006
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Resistance to echinocandin-class antifungal drugs. Drug Resist Updat (2007) 4.63
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis (2013) 4.14
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol (2007) 3.57
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother (2006) 3.19
Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother (2008) 3.05
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother (2008) 2.54
Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol (2010) 2.47
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol (2009) 2.47
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother (2008) 2.41
Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother (2009) 2.41
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother (2007) 2.20
Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog (2008) 2.19
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother (2008) 2.13
Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev (2011) 1.90
In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother (2010) 1.88
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother (2010) 1.79
Fungal echinocandin resistance. Fungal Genet Biol (2009) 1.78
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother (2010) 1.68
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol (2010) 1.68
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother (2007) 1.61
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother (2012) 1.44
A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 1.44
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother (2006) 1.43
Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother (2011) 1.39
Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol (2008) 1.29
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother (2008) 1.28
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol (2010) 1.26
Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother (2007) 1.26
Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother (2011) 1.25
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother (2011) 1.25
Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.22
Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol (2011) 1.20
Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis (2009) 1.20
Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2009) 1.19
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother (2012) 1.13
Mechanisms of Candida biofilm drug resistance. Future Microbiol (2013) 1.13
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol (2008) 1.13
Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother (2012) 1.11
Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother (2011) 1.10
Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs (2014) 1.10
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur J Med Res (2011) 1.08
In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother (2006) 1.06
Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother (2013) 1.05
Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. J Clin Microbiol (2011) 1.04
Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis (2014) 1.02
FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother (2010) 1.01
In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc (2008) 0.97
Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates. Antimicrob Agents Chemother (2011) 0.93
Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res (2011) 0.92
Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother (2012) 0.91
In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob Agents Chemother (2009) 0.89
Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J Clin Microbiol (2011) 0.88
Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis (2015) 0.87
Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob Agents Chemother (2012) 0.86
Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections. Can J Infect Dis Med Microbiol (2008) 0.85
Mutants in the Candida glabrata glycerol channels are sensitized to cell wall stress. Eukaryot Cell (2012) 0.84
Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci (2015) 0.84
Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol (2010) 0.82
Particular Candida albicans strains in the digestive tract of dyspeptic patients, identified by multilocus sequence typing. PLoS One (2012) 0.81
Clonal Strain Persistence of Candida albicans Isolates from Chronic Mucocutaneous Candidiasis Patients. PLoS One (2016) 0.80
Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy. Antimicrob Agents Chemother (2015) 0.80
A single-centre 10-year experience with Candida bloodstream infections. Can J Infect Dis Med Microbiol (2009) 0.79
Review of the pharmacology and clinical studies of micafungin. Drug Des Devel Ther (2009) 0.78
Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci (2010) 0.77
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infect Drug Resist (2009) 0.76
New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study. BMC Infect Dis (2015) 0.76
Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections. Clin Med Insights Pediatr (2012) 0.75
Anidulafungin and its role in candida infections. Infect Drug Resist (2009) 0.75
Anidulafungin: an evidence-based review of its use in invasive fungal infections. Core Evid (2008) 0.75
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis (2009) 4.71
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis (2013) 4.14
2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect (2010) 3.56
Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol (2007) 3.43
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother (2009) 3.13
Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother (2008) 3.05
Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol (2002) 3.01
Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother (2003) 2.83
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis (2013) 2.65
Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol (2010) 2.47
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother (2008) 2.44
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother (2008) 2.41
Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother (2009) 2.41
Complementary adhesin function in C. albicans biofilm formation. Curr Biol (2008) 2.41
Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother (2006) 2.37
Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis (2013) 2.31
Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents (2006) 2.30
Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy (2006) 2.30
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother (2007) 2.20
Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother (2007) 2.18
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Role of the fungal Ras-protein kinase A pathway in governing epithelial cell interactions during oropharyngeal candidiasis. Cell Microbiol (2005) 2.15
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother (2008) 2.13
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS (2003) 2.11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06
Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis (2014) 1.86
Fungal invasion of normally non-phagocytic host cells. PLoS Pathog (2006) 1.83
Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis (2005) 1.83
High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis (2011) 1.72
Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr (2011) 1.71
Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother (2010) 1.68
In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother (2004) 1.62
Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. PLoS Pathog (2010) 1.58
Rapid real-time nucleic Acid sequence-based amplification-molecular beacon platform to detect fungal and bacterial bloodstream infections. J Clin Microbiol (2009) 1.58
A selective, Bayesian approach to intraoperative PTH monitoring. Ann Surg (2010) 1.56
Functional analysis of the Candida albicans ALS1 gene product. Yeast (2004) 1.50
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol (2012) 1.49
Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother (2008) 1.46
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother (2012) 1.44
A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 1.44
Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother (2013) 1.44
Transcriptional profiling identifies a role for BrlA in the response to nitrogen depletion and for StuA in the regulation of secondary metabolite clusters in Aspergillus fumigatus. Eukaryot Cell (2008) 1.41
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis (2012) 1.40
Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother (2011) 1.39
Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus. Eukaryot Cell (2008) 1.37
Multilocus sequence typing is a reliable alternative method to DNA fingerprinting for discriminating among strains of Candida albicans. J Clin Microbiol (2004) 1.33
Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS (2009) 1.32
Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole. J Clin Microbiol (2005) 1.29
Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr (2007) 1.28
Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob Agents Chemother (2002) 1.26
Mechanism of the synergistic effect of amiodarone and fluconazole in Candida albicans. Antimicrob Agents Chemother (2010) 1.26
Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens. Antimicrob Agents Chemother (2007) 1.24
The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24
Candida albicans protein kinase CK2 governs virulence during oropharyngeal candidiasis. Cell Microbiol (2006) 1.21
A fungus-specific ras homolog contributes to the hyphal growth and virulence of Aspergillus fumigatus. Eukaryot Cell (2005) 1.21
The role of mast cells in the defence against pathogens. PLoS Pathog (2012) 1.21
Aspergillus fumigatus MedA governs adherence, host cell interactions and virulence. Cell Microbiol (2009) 1.18
Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplification. J Clin Microbiol (2010) 1.17
Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis (2002) 1.16
Aspergillus galactosaminogalactan mediates adherence to host constituents and conceals hyphal β-glucan from the immune system. PLoS Pathog (2013) 1.15
Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol (2011) 1.14
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother (2012) 1.13
Echovirus 30, Jiangsu Province, China. Emerg Infect Dis (2005) 1.12
Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis (2011) 1.11
Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis (2005) 1.10
Evaluation of fluconazole resistance mechanisms in candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis (2004) 1.10
Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother (2013) 1.10
A real-time PCR assay for rapid detection and quantification of Exserohilum rostratum, a causative pathogen of fungal meningitis associated with injection of contaminated methylprednisolone. J Clin Microbiol (2013) 1.09
Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol (2011) 1.08
Role of trehalose biosynthesis in Aspergillus fumigatus development, stress response, and virulence. Infect Immun (2010) 1.08
Aspergillus fumigatus stimulates leukocyte adhesion molecules and cytokine production by endothelial cells in vitro and during invasive pulmonary disease. Infect Immun (2008) 1.05
Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J Immunol (2010) 1.05
Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother (2004) 1.05
Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS (2004) 1.04
TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine (2010) 1.04